Novel antibody-peptide conjugate for combatting Neisseria gonorrhoea resistance

Applications: Novel antimicrobials

A novel antibody-peptide conjugate comprised of Oct-TriA₁covalently linked to an anti-N. gonorrhoeae monoclonal antibody. The linker can only be cleaved by certain species of bacteria, resulting in a highly specific therapeutic.

Features	Benefits
Linker that can only be cleaved by a protease secreted by the gonococcus	Specific and selective killing of pathogenic microbes
Oct-TriA₁is a highly efficacious antibacterial agent	Effective killing of N. gonorrhoeae
Therapeutic is only released in the presence of the gonococcal IgA protease	Minimises non-selective host cell cytotoxicity that limits use of antimicrobial peptides
Modular, plug and play system for targeting, release, and killing of bacterial pathogens	Technology can be adapted for other pathogenic bacteria
Monoclonal antibody can be functionalised	Activation of immune killing to potentiate the antimicrobial

Available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

Novel antibody-peptide conjugate for combatting Neisseria gonorrhoea resistance

Ready to get in touch?